175 related articles for article (PubMed ID: 23512326)
1. Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients.
Lund JL; Stürmer T; Sanoff HK; Brookhart A; Sandler RS; Warren JL
Cancer; 2013 Jun; 119(11):2038-47. PubMed ID: 23512326
[TBL] [Abstract][Full Text] [Related]
2. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
Panchal JM; Lairson DR; Chan W; Du XL
Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
[TBL] [Abstract][Full Text] [Related]
4. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.
Sanoff HK; Carpenter WR; Stürmer T; Goldberg RM; Martin CF; Fine JP; McCleary NJ; Meyerhardt JA; Niland J; Kahn KL; Schymura MJ; Schrag D
J Clin Oncol; 2012 Jul; 30(21):2624-34. PubMed ID: 22665536
[TBL] [Abstract][Full Text] [Related]
5. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
Mack CD; Carpenter W; Meyer AM; Sanoff H; Stürmer T
Cancer; 2012 Jun; 118(11):2925-34. PubMed ID: 22072441
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
8. Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer.
Abrams TA; Brightly R; Mao J; Kirkner G; Meyerhardt JA; Schrag D; Fuchs CS
J Clin Oncol; 2011 Aug; 29(24):3255-62. PubMed ID: 21768462
[TBL] [Abstract][Full Text] [Related]
9. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Iveson TJ; Kerr RS; Saunders MP; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Scudder C; Boyd KA; Briggs A; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan HS; Paul J
Lancet Oncol; 2018 Apr; 19(4):562-578. PubMed ID: 29611518
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of oxaliplatin-based adjuvant chemotherapy in stage II and III colorectal cancer with perforation].
Onozawa H; Hatano S; Matsuzawa T; Kuwabara K; Ishiguro T; Sobajima J; Kumamoto K; Fukuchi M; Kumagai Y; Baba H; Ishibashi K; Mochiki E; Ishida H
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1749-51. PubMed ID: 25731317
[TBL] [Abstract][Full Text] [Related]
11. Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer.
Raphael MJ; Fischer HD; Fung K; Austin PC; Anderson GM; Booth CM; Singh S
Clin Colorectal Cancer; 2017 Dec; 16(4):397-404.e1. PubMed ID: 28434884
[TBL] [Abstract][Full Text] [Related]
12. The use of chemotherapy in older patients with stage II and III colon cancer: Variation by age and era of diagnosis.
Green SL; Dawe DE; Nugent Z; Cheung WY; Czaykowski PM
J Geriatr Oncol; 2019 Jan; 10(1):132-137. PubMed ID: 30104156
[TBL] [Abstract][Full Text] [Related]
13. Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6.
Laurent M; Des Guetz G; Bastuji-Garin S; Culine S; Caillet P; Aparicio T; Audureau E; Carvahlo-Verlinde M; Reinald N; Tournigand C; Landre T; LeThuaut A; Paillaud E; Canouï-Poitrine F
Am J Clin Oncol; 2018 Jan; 41(1):73-80. PubMed ID: 26669742
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community.
Protásio BM; Matutino A; Lage LV; Santana I; Ramos R; Sabbaga J; Capareli F; Saragiotto D; Riechelmann R; Hoff PM
Clin Colorectal Cancer; 2017 Mar; 16(1):65-72. PubMed ID: 27515842
[TBL] [Abstract][Full Text] [Related]
15. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.
Sanoff HK; Carpenter WR; Freburger J; Li L; Chen K; Zullig LL; Goldberg RM; Schymura MJ; Schrag D
Cancer; 2012 Sep; 118(17):4309-20. PubMed ID: 22294436
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Colorectal Cancer Care in the United States: 1990-2010.
Murphy CC; Harlan LC; Lund JL; Lynch CF; Geiger AM
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26206950
[TBL] [Abstract][Full Text] [Related]
17. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
Ejaz A; Casadaban L; Maker AV
J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
[TBL] [Abstract][Full Text] [Related]
18. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
Lin WR; Chiang JM; Liang KH; Lim SN; Lai MW; Tsou YK; Hsieh TY; Hsu CK; Yeh CT
Medicine (Baltimore); 2016 Apr; 95(17):e3487. PubMed ID: 27124048
[TBL] [Abstract][Full Text] [Related]
19. [Tolerability of Oxaliplatin-Based Adjuvant Chemotherapy for Patients with Colorectal Cancer].
Matsuo H; Nakanishi M; Arita T; Murayama Y; Kuriu Y; Kosuga T; Konishi H; Morimura R; Komatsu S; Shiozaki A; Ikoma H; Ichikawa D; Fujiwara H; Okamoto K; Otsuji E
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2112-4. PubMed ID: 26805281
[TBL] [Abstract][Full Text] [Related]
20. Colorectal cancer surgery in portal hypertensive patients: does adjuvant oxaliplatin affect prognosis?
Madbouly KM; Hussein AM; Zeid A
Dis Colon Rectum; 2013 May; 56(5):577-85. PubMed ID: 23575396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
